Navigation Links
Omthera Pharmaceuticals, Inc. Announces Pricing of Initial Public Offering
Date:4/11/2013

tion in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

About Omthera Pharmaceuticals, Inc.

Omthera Pharmaceuticals, Inc. (the "Company") is an emerging specialty pharmaceutical company focused on the development and commercialization of new therapies for dyslipidemia and the treatment of cardiovascular disease. Epanova, currently the Company's sole product candidate, is a late-stage, novel, omega-3 free fatty acid composition that meaningfully reduces triglycerides, improves other key lipid parameters and is expected to increase patient convenience with 2-gram once-a-day dosing with or without meals. Epanova is a coated soft gelatin capsule containing a complex mixture of polyunsaturated free fatty acids derived from fish oils, including multiple long-chain omega-3 and omega-6 fatty acids, with EPA, DHA, and docosapentaenoic acid being the most abundant forms of omega-3 fatty acids. The Company has completed pharmacokinetic and Phase III clinical studies to investigate the safety and efficacy profile of Epanova. In 2012 the Company reported positive results from its Phase III EVOLVE and ESPRIT trials, both of which were conducted under SPA agreements with the U.S. Food and Drug Administration. Omthera holds worldwide rights to Epanova under a license from Chrysalis Pharma AG, a privately held Swiss company that is the owner of the product.

Omthera maintains a website at www.omthera.com.  

Omthera Contact:
Christian Schade
Executive Vice President & Chief Financial Officer
Omthera Pharmaceuticals
T: 908-741-4399
E: CSchade@Omthera.com

 


'/>"/>
SOURCE Omthera Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Omthera Pharmaceuticals Announces Positive Top-Line Results from Phase 3 EVOLVE Study
2. Omthera Pharmaceuticals Announces Invitation to Attend Presentation of the Complete Data Sets from its Phase 3 EVOLVE and ESPRIT Clinical Studies
3. Omthera Pharmaceuticals Presents Data From Analysis Of EVOLVE Trial Showing That Epanova Lowers ApoC-III, A Key Predictor of Cardiovascular Risk
4. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
5. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
6. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
7. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
8. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
9. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
10. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
11. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... WHITEHOUSE STATION, N.J. , Sept. 19, 2014 Merck ... the United States and Canada , ... on Desafiando La Diabetes: Logra Tus Metas , an educational ... of their blood sugar -- a key treatment goal to help ... the United States are at a higher risk for ...
(Date:9/19/2014)... 19, 2014 UBM Medica US announces that  ... community to help oncologists and other clinicians gain a ... use of targeted therapies and immunotherapies, discusses some of ... Every September, Blood Cancer Awareness ... awareness about blood cancers—helping to increase survival rates and ...
(Date:9/19/2014)... 2014 According to market ... Mobile, Industrial, & Laboratory), Industry (Food, Pharmaceutical, Biotechnology, ... Rotary) & Geography - Global Trends & Forecast ... the lyophilization market on the basis of various ... of the market size of each of these ...
Breaking Medicine Technology:Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 2Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 3Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 4Celebrity Chef Leticia Moreinos Schwartz Partners with Merck on Desafiando La Diabetes: Logra Tus Metas to Urge Hispanics With Type 2 Diabetes to Get to Their A1C Goal 5OncoTherapy Network Highlights National Blood Cancer Awareness Month 2OncoTherapy Network Highlights National Blood Cancer Awareness Month 3OncoTherapy Network Highlights National Blood Cancer Awareness Month 4Lyophilization Market Worth $5,121.5 Million by 2019 2Lyophilization Market Worth $5,121.5 Million by 2019 3
(Date:9/19/2014)... In partnership with Raw Beauty NYC, ... of the project’s social media efforts. StudioPMG is honored to ... the perception of beauty as it applies to disabled women. ... by Shelly Baer and Vanessa Silberman, who wanted to create ... beautiful. Ginny Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen ...
(Date:9/19/2014)... violence occurs at least as frequently, and likely ... opposite-sex couples, according to a review of literature ... studies, when analyzed together, indicate that domestic violence ... gay and bisexual individuals. However, a lack of ... incomplete picture of the true landscape, suggesting even ...
(Date:9/19/2014)... Mayo Clinic have discovered a defect in a key ... toxic protein in the brains of Alzheimer,s disease ... neurons both significant contributors to this type of ... Neuron , offers the potential that ... rescue this pathway," says the study,s lead investigator, ...
(Date:9/19/2014)... September 20, 2014 As summer vacations end ... in Queens, NY now reminds area patients about the reality ... of our population affected by gum disease, there is simply ... For over 20 years Dr. Krishnan has treated patients with ... location. “Most patients that come in due to common symptoms ...
(Date:9/19/2014)... 2014 (HealthDay News) -- More states are passing legislation ... to use for any child having a severe allergic ... "anaphylaxis," an allergic reaction that can lead to throat ... and even death. In people with severe ... nuts, insect venom or certain drugs, anaphylaxis can occur ...
Breaking Medicine News(10 mins):Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:Domestic violence likely more frequent for same-sex couples 2Health News:Mayo researchers reveal pathway that contributes to Alzheimer's disease 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 2Health News:More Schools Stocking Shots That Counter Serious Allergic Reactions 3
... , FRIDAY, Aug. 12 (HealthDay News) -- Religious ... facing hardship or conflict, a new study indicates. ... such link. Not only are fewer people religious ... in regions where there,s hardship and strife, regardless of ...
... HealthDay Reporter , THURSDAY, Aug. 11 (HealthDay News) -- Depressed ... suggests. "We know that stroke can increase risk of ... said study author An Pan, a research scientist at the ... associated with hormonal changes in the body and affects chemicals ...
... (HealthDay News) -- Obstructive sleep apnea (OSA) and sleepiness rapidly ... machines, a new study finds. CPAP is a common ... during sleep due to the repeated blockage of the upper ... stream of air through a mask or nose piece the ...
... of continuous positive airway pressure machines (CPAP) for patients ... the therapy is withdrawn, according to Swiss research. ... the American Thoracic Society,s American Journal of Respiratory ... obstructive sleep apnea who are established on CPAP treatment, ...
... in illness and recovery is a primary influence upon ... a first-of-its-kind study has discovered. Outreach and education efforts ... concerns and improve health care quality in this rapidly ... fasting occurring this month is but one of many ...
... Researchers from the Indiana University have identified common ... in Intensive Care Units (ICUs). The study, published ... and Hospital Epidemiology , the journal of the ... lessons learned from six ICUs as they implemented ...
Cached Medicine News:Health News:Religion Might Boost Happiness in Times of Stress 2Health News:Depressed Women Could Face Raised Risk of Stroke 2Health News:Depressed Women Could Face Raised Risk of Stroke 3Health News:Withdrawal of CPAP therapy results in rapid recurrence of OSA 2Health News:Religious beliefs shape health care attitudes among US Muslims 2Health News:Religious beliefs shape health care attitudes among US Muslims 3Health News:Common themes emerge in hospitals' anti-MRSA efforts: Study 2
... is a mechanical catheter intended to percutaneously ... access grafts. The disposable catheter requires no ... spiral shaft which extends beyond the 6F ... tip. In use, the tip spins to ...
... HYDROLYSER Percutaneous Thrombectomy Catheter is ... for rapid, effective and easy removal ... shunts. The HYDROLYSER catheter provides an ... thrombolytic therapy. ,Compatible with ...
Introduced more than 30 years ago by Dr. Thomas J. Fogarty, these embolectomy catheters are indicated for the removal of fresh, soft emboli and thrombi from vessels in the arterial system....
... The AVX catheter is designed to ... 12mm. High-pressure saline jets travel backwards ... to create a low pressure zone ... drawn into the catheter where it ...
Medicine Products: